Abstract 390P
Background
The intensive incidence rate of oropharyngeal cancer in Uzbekistan has increased over the past 7 years from 1.4 to 2.0 per 100,000 population in 2022, and the proportion of active detection has increased from 25.9 to 32.9%.
Methods
A retrospective analysis of the causes and prevalence of oropharyngeal cancer in the Republic of Uzbekistan was performed. The object of the study were 582 patients from database of RSSPMC of Oncology and Radiology of Uzbekistan who were treated for the period 2020-2022. The study of risk factors was carried out according to gradations: smoking, use of a local variety of tobacco - nasvay, alcohol consumption, a history of trauma, a resident of an urban area, working in gas contamination conditions and dustiness. There were 471 men (80.9%), women - 101 (19.1%). The mean age was 47.3±1.5.
Results
A study of geographical indicators demonstrated that the most common oropharyngeal cancer caused by the use of nasvay occurred in patients from the eastern and southern regions of the republic - 327 (56.2%). In these patients, the average duration of tobacco use was more than 7 years. In contrast, poor climatic conditions caused the development of oral cancer in 89 (15.3%) patients from the Aral Sea region (northwest). The remaining 166 (28.5%) patients were in the central regions of Uzbekistan. When studying risk factors, the vast majority of patients (411 (70.6%)) used nasvay as a bad habit. At the same time, 174 (42.3%) of 411 patients also had smoking and alcohol consumption. Despite the impact of the dusty climate in the Aral Sea zone, 81 (91.0%) patients had a history of alcohol consumption, 19 (21.3%) - smoking. 218 (37.5%) urban residents developed oral cancer due to bad habits (smoking - 174, alcohol - 147, nasvay - 53).
Conclusions
Thus, the analysis of the epidemiological aspects of the development of oral cancer in Uzbekistan indicates that this disease is quite widespread and tends to grow. The main factor is bad habits, in particular the widespread use of nasvay. Only, in the urban population, the influence of nasvay on the development of cancer becomes less, but due to the prevalence of smoking and alcohol abuse, it requires further study to identify specific ways to manage oral cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Tashkent medical academy.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
561P - Mechanisms of osimertinib resistance using circulating tumor DNA analyses for EGFR-mutated non-small cell lung cancer, results from ELUCIDATOR: A prospective observational multicenter study
Presenter: Daijiro Harada
Session: Poster Display
Resources:
Abstract
562P - First-line (1L) osimertinib (osi) ± platinum-pemetrexed in patients (pts) with EGFRm advanced NSCLC: FLAURA2 China cohort
Presenter: Yan Yu
Session: Poster Display
Resources:
Abstract
563P - Real-world effectiveness and safety of first-line osimertinib for EGFR-mutated advanced NSCLC in China (FLOURISH study)
Presenter: Jianya Zhou
Session: Poster Display
Resources:
Abstract
564P - Co-occurring EGFR p.E709X mutation affects the treatment response to the third-generation EGFR-TKIs in EGFR p.G719X-mutant patients with advanced NSCLC
Presenter: Wen Feng Fang
Session: Poster Display
Resources:
Abstract
565P - Genome-guided targeted therapy combination improves survival in patients with advanced EGFR mutation positive NSCLC failing osimertinib
Presenter: Molly Li
Session: Poster Display
Resources:
Abstract
566P - Safety of tepotinib + osimertinib in EGFR-mutant NSCLC with MET amplification after first-line osimertinib
Presenter: Chong Kin Liam
Session: Poster Display
Resources:
Abstract
567P - Furmonertinib in combination with bevacizumab and intrathecal chemotherapy as later-line re-challenge treatment in EGFR –mutated NSCLC patients with leptomeningeal metastasis after third-generation EGFR-TKIs treatment failure
Presenter: Fang Cun
Session: Poster Display
Resources:
Abstract
568P - First-line (1L) osimertinib + platinum-pemetrexed in EGFR-mutated (EGFRm) advanced NSCLC: Updated FLAURA2 safety run-in (SRI) results
Presenter: David Planchard
Session: Poster Display
Resources:
Abstract
569P - Whole-transcriptome sequencing of transformed small-cell lung cancer from EGFR-mutated lung adenocarcinoma reveals LUAD–like and SCLC–like subsets
Presenter: Chan-Yuan Zhang
Session: Poster Display
Resources:
Abstract
570P - First-line osimertinib for patients with advanced NSCLC harboring EGFR mutations: A real-world study
Presenter: Wenxiang Ji
Session: Poster Display
Resources:
Abstract